A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE
This research study is looking at a new medicine, INCB099280, for adults who have certain types of solid cancers that are advanced or have come back. These cancers have not been treated with a specific type of cancer treatment called 'immunotherapy' before. The main goals are to find out if this medicine can shrink tumors and how safe it is for patients. Researchers will closely watch for any side effects and how patients are responding to the treatment. This is a Phase 2 study, meaning it's an important step in understanding if the medicine could help patients in the future, by checking its effectiveness and safety in a larger group of people.
At a glance
What is this study about?
This study is a research project focusing on a new medicine called INCB099280. It's designed for people who have certain types of advanced solid cancers that have spread or returned. Importantly, these patients will not have had a specific kind of cancer treatment called 'immunotherapy' before. Researchers want to see if this new medicine can help by shrinking tumors and if it's safe for people to take.
Think of it like this: when developing a new medicine, it goes through different stages. This is a `Phase 2` study. This means the medicine has already been tested in a smaller group of people (Phase 1) to check its basic safety. Now, in Phase 2, the researchers want to learn more about how well it works and look for side effects in a larger group of patients. They will be carefully watching to see if the cancer responds to the treatment, which could mean tumors getting smaller or not growing.
The information gathered from this study is really important. It helps doctors understand if INCB099280 has the potential to become a new treatment option for specific cancers in the future. By joining, participants contribute to a better understanding of cancer and how new medicines might help patients. Your involvement helps advance medical science.
Key takeaways
- This study is testing a new medicine, INCB099280, for certain advanced solid cancers.
- It's for people who haven't had a specific type of immunotherapy called immune checkpoint inhibitor.
- The main goals are to see if the medicine shrinks tumors and is safe to use.
- Participation involves regular visits for checks, blood tests, and scans.
- It's a Phase 2 study, an important step in understanding new treatments.
- You can withdraw from the study at any time.
Who may be eligible?
To join this study, you need to be an adult, 18 years or older, regardless of whether you are male or female. The study is for people who have certain types of solid cancers that are considered advanced, meaning they have spread, or have come back after previous treatment.
A key requirement is that you must not have received a treatment called 'immune checkpoint inhibitor' before. This is a specific type of immunotherapy. You might have had other cancer treatments in the past, or this could be the first treatment you're having for your cancer.
These are general points, and a full check of your medical history would be done by the study team to see if this trial is the right fit for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of advanced or recurrent solid cancer?
- Have you *never* received an 'immune checkpoint inhibitor' (a type of immunotherapy)?
- Are you able to attend regular hospital/clinic visits for monitoring?
What does participation involve?
If you decide to take part, you would receive the study medicine, INCB099280. You would have regular visits to the hospital or clinic. During these visits, doctors and nurses would perform physical exams, check your vital signs (like blood pressure and heart rate), and take blood or urine samples. They would also do scans to see how your cancer is responding to the medicine.
These checks are important for monitoring your health, looking for any side effects, and seeing if the treatment is working. The exact number of visits and the total length of time you'd be in the study can vary, but the study team would explain the full schedule to you before you commit. You would have ongoing support from the study team throughout your participation.
Potential risks and benefits
Locations (3)
- —UnverifiedRomania
- —UnverifiedHungary
- —UnverifiedGreece
Common questions
What is INCB099280?
It's a new investigational medicine being tested in this study to see if it can help treat certain advanced solid cancers.
What does 'immunotherapy-naïve' mean?
It means you have not had a specific type of cancer treatment called 'immune checkpoint inhibitor' before.
Will this medicine cure my cancer?
This is a research study, and while the aim is to find effective treatments, there's no guarantee of a cure. We are evaluating its effectiveness.
How long would I be in the study?
The duration of participation varies. The study team will explain the expected timeline and visit schedule if you are eligible.
Can I stop participating if I want to?
Yes, absolutely. You can leave the study at any time, for any reason, without it affecting your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.